Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1989 1
1990 1
1993 1
1995 1
1996 3
1997 3
1998 10
1999 14
2000 16
2001 13
2002 20
2003 21
2004 37
2005 50
2006 84
2007 104
2008 248
2009 349
2010 449
2011 692
2012 1192
2013 1427
2014 1490
2015 1278
2016 1336
2017 1112
2018 996
2019 1289
2020 1249
2021 976
2022 901
2023 695
2024 333

Text availability

Article attribute

Article type

Publication date

Search Results

13,920 results

Results by year

Filters applied: . Clear all
Page 1
Clinical trial design in the era of precision medicine.
Fountzilas E, Tsimberidou AM, Vo HH, Kurzrock R. Fountzilas E, et al. Genome Med. 2022 Aug 31;14(1):101. doi: 10.1186/s13073-022-01102-1. Genome Med. 2022. PMID: 36045401 Free PMC article. Review.
DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms.
Yao J, Bergsland E, Aggarwal R, Aparicio A, Beltran H, Crabtree JS, Hann CL, Ibrahim T, Byers LA, Sasano H, Umejiego J, Pavel M. Yao J, et al. Oncologist. 2022 Nov 3;27(11):940-951. doi: 10.1093/oncolo/oyac161. Oncologist. 2022. PMID: 35983951 Free PMC article. Review.
Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia.
Daver N, Perl AE, Maly J, Levis M, Ritchie E, Litzow M, McCloskey J, Smith CC, Schiller G, Bradley T, Tiu RV, Naqvi K, Dail M, Brackman D, Siddani S, Wang J, Chyla B, Lee P, Altman JK. Daver N, et al. J Clin Oncol. 2022 Dec 10;40(35):4048-4059. doi: 10.1200/JCO.22.00602. Epub 2022 Jul 18. J Clin Oncol. 2022. PMID: 35849791 Free PMC article. Clinical Trial.
Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial.
Jabbour E, Short NJ, Senapati J, Jain N, Huang X, Daver N, DiNardo CD, Pemmaraju N, Wierda W, Garcia-Manero G, Montalban Bravo G, Sasaki K, Kadia TM, Khoury J, Wang SA, Haddad FG, Jacob J, Garris R, Ravandi F, Kantarjian HM. Jabbour E, et al. Lancet Haematol. 2023 Jun;10(6):e433-e444. doi: 10.1016/S2352-3026(23)00073-X. Epub 2023 May 12. Lancet Haematol. 2023. PMID: 37187201 Clinical Trial.
TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer.
Ai D, Yao J, Yang F, Huo L, Chen H, Lu W, Soto LMS, Jiang M, Raso MG, Wang S, Bell D, Liu J, Wang H, Tan D, Torres-Cabala C, Gan Q, Wu Y, Albarracin C, Hung MC, Meric-Bernstam F, Wistuba II, Prieto VG, Sahin AA, Ding Q. Ai D, et al. Mod Pathol. 2021 Apr;34(4):710-719. doi: 10.1038/s41379-020-00692-8. Epub 2020 Oct 3. Mod Pathol. 2021. PMID: 33011748 Free article.
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia.
Mato AR, Woyach JA, Brown JR, Ghia P, Patel K, Eyre TA, Munir T, Lech-Maranda E, Lamanna N, Tam CS, Shah NN, Coombs CC, Ujjani CS, Fakhri B, Cheah CY, Patel MR, Alencar AJ, Cohen JB, Gerson JN, Flinn IW, Ma S, Jagadeesh D, Rhodes JM, Hernandez-Ilizaliturri F, Zinzani PL, Seymour JF, Balbas M, Nair B, Abada P, Wang C, Ruppert AS, Wang D, Tsai DE, Wierda WG, Jurczak W. Mato AR, et al. N Engl J Med. 2023 Jul 6;389(1):33-44. doi: 10.1056/NEJMoa2300696. N Engl J Med. 2023. PMID: 37407001 Clinical Trial.
13,920 results
You have reached the last available page of results. Please see the User Guide for more information.